一项使用新药 Nivolumab 与化疗药物联合治疗鼻咽癌 (NPC) 的研究
使用吉西他滨、顺铂和纳武单抗化学免疫疗法治疗新诊断鼻咽癌 (NPC) 的 2 期研究
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
研究概览
地位
干预/治疗
- 其他:Quality-of-Life Assessment
- 药品:Cisplatin
- 程序:Computed Tomography
- 程序:Magnetic Resonance Imaging
- 其他:Questionnaire Administration
- 程序:Echocardiography Test
- 程序:Multigated Acquisition Scan
- 程序:Positron Emission Tomography
- 生物:Nivolumab
- 药品:Gemcitabine
- 程序:Biopsy Procedure
- 程序:Chest Radiography
- 其他:Electronic Health Record Review
- 辐射:Radiation Therapy
- 程序:Biospecimen Collection
- 其他:Fluciclovine F18
- 程序:X-Ray Imaging
详细说明
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor, blood and stool) for future research studies.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy, blood and stool sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T3B 6A8
- 招聘中
- Alberta Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:403-220-6898
- 邮箱:research4kids@ucalgary.ca
-
首席研究员:
- Victor A. Lewis
-
Edmonton、Alberta、加拿大、T6G 2B7
- 招聘中
- University of Alberta Hospital
-
接触:
- Site Public Contact
- 电话号码:780-407-8798
- 邮箱:pedsoncologyresearch@ahs.ca
-
首席研究员:
- Sarah J. McKillop
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 1X8
- 招聘中
- Hospital for Sick Children
-
接触:
- Site Public Contact
- 电话号码:416-813-7654
- 邮箱:ask.CRS@sickkids.ca
-
首席研究员:
- Avram E. Denburg
-
-
Quebec
-
Montreal、Quebec、加拿大、H3H 1P3
- 招聘中
- The Montreal Children's Hospital of the MUHC
-
接触:
- Site Public Contact
- 电话号码:514-412-4445
- 邮箱:info@thechildren.com
-
首席研究员:
- Stephanie Mourad
-
Montreal、Quebec、加拿大、H3T 1C5
- 招聘中
- Centre Hospitalier Universitaire Sainte-Justine
-
首席研究员:
- Monia Marzouki
-
接触:
- Site Public Contact
- 电话号码:514-345-4931
- 邮箱:yvan.samson@umontreal.ca
-
Sherbrooke、Quebec、加拿大、J1H 5N4
- 招聘中
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
接触:
- Site Public Contact
- 电话号码:819-820-6480
- 邮箱:crcinformation.chus@ssss.gouv.qc.ca
-
首席研究员:
- Stephanie Vairy
-
-
-
-
-
Christchurch、新西兰、8011
- 招聘中
- Christchurch Hospital
-
首席研究员:
- Tristan Pettit
-
接触:
- Site Public Contact
- 电话号码:03 364 0640
-
-
Auckland
-
Grafton、Auckland、新西兰、1145
- 招聘中
- Starship Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:0800 728 436
-
首席研究员:
- Leander D. Timothy
-
-
-
-
-
San Juan、波多黎各、00926
- 招聘中
- University Pediatric Hospital
-
接触:
- Site Public Contact
- 电话号码:787-474-0333
-
首席研究员:
- Maria E. Echevarria
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre、New South Wales、澳大利亚、2310
- 招聘中
- John Hunter Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:(02) 4985 5180
-
首席研究员:
- Kristy McCarthy
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 招聘中
- Children's Hospital of Alabama
-
接触:
- Site Public Contact
- 电话号码:205-638-9285
- 邮箱:oncologyresearch@peds.uab.edu
-
首席研究员:
- Jamie M. Aye
-
-
Arizona
-
Phoenix、Arizona、美国、85016
- 招聘中
- Phoenix Childrens Hospital
-
接触:
- Site Public Contact
- 电话号码:602-546-0920
-
首席研究员:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock、Arkansas、美国、72202-3591
- 招聘中
- Arkansas Children's Hospital
-
首席研究员:
- Michael W. Bishop
-
接触:
- Site Public Contact
- 电话号码:501-364-7373
-
-
California
-
Downey、California、美国、90242
- 招聘中
- Kaiser Permanente Downey Medical Center
-
接触:
- Site Public Contact
- 电话号码:626-564-3455
-
首席研究员:
- Robert M. Cooper
-
Loma Linda、California、美国、92354
- 招聘中
- Loma Linda University Medical Center
-
接触:
- Site Public Contact
- 电话号码:909-558-4050
-
首席研究员:
- Albert Kheradpour
-
Los Angeles、California、美国、90027
- 招聘中
- Children's Hospital Los Angeles
-
首席研究员:
- Rachana Shah
-
接触:
- Site Public Contact
- 电话号码:323-361-4110
-
Madera、California、美国、93636
- 招聘中
- Valley Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:559-353-3000
- 邮箱:Research@valleychildrens.org
-
首席研究员:
- Ruetima Titapiwatanakun
-
Oakland、California、美国、94611
- 招聘中
- Kaiser Permanente-Oakland
-
接触:
- Site Public Contact
- 电话号码:877-642-4691
- 邮箱:Kpoct@kp.org
-
首席研究员:
- Aarati V. Rao
-
Oakland、California、美国、94609
- 招聘中
- UCSF Benioff Children's Hospital Oakland
-
首席研究员:
- Jennifer G. Michlitsch
-
接触:
- Site Public Contact
- 电话号码:510-428-3264
- 邮箱:PedOncRschOAK@ucsf.edu
-
San Diego、California、美国、92123
- 招聘中
- Rady Children's Hospital - San Diego
-
接触:
- Site Public Contact
- 电话号码:858-966-5934
-
首席研究员:
- William D. Roberts
-
San Francisco、California、美国、94158
- 招聘中
- UCSF Medical Center-Mission Bay
-
接触:
- Site Public Contact
- 电话号码:877-827-3222
- 邮箱:cancertrials@ucsf.edu
-
首席研究员:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- Children's Hospital Colorado
-
首席研究员:
- Navin R. Pinto
-
接触:
- Site Public Contact
- 电话号码:303-764-5056
- 邮箱:josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- 招聘中
- Connecticut Children's Medical Center
-
接触:
- Site Public Contact
- 电话号码:860-545-9981
-
首席研究员:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington、Delaware、美国、19803
- 招聘中
- Alfred I duPont Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- 招聘中
- Children's National Medical Center
-
首席研究员:
- Jeffrey S. Dome
-
接触:
- Site Public Contact
- 电话号码:202-476-2800
- 邮箱:OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville、Florida、美国、32610
- 招聘中
- UF Health Cancer Institute - Gainesville
-
接触:
- Site Public Contact
- 电话号码:352-273-8010
- 邮箱:cancer-center@ufl.edu
-
首席研究员:
- Brian Stover
-
Jacksonville、Florida、美国、32207
- 招聘中
- Nemours Children's Clinic-Jacksonville
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Sridhi Patel
-
Miami、Florida、美国、33155
- 招聘中
- Nicklaus Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:888-624-2778
-
首席研究员:
- Ziad A. Khatib
-
Orlando、Florida、美国、32806
- 招聘中
- Arnold Palmer Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:321-841-5357
- 邮箱:Jennifer.spinelli@orlandohealth.com
-
首席研究员:
- Zhongbo Hu
-
Orlando、Florida、美国、32827
- 招聘中
- Nemours Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:302-651-5572
- 邮箱:Allison.bruce@nemours.org
-
首席研究员:
- Sridhi Patel
-
Pensacola、Florida、美国、32504
- 招聘中
- Nemours Children's Clinic - Pensacola
-
接触:
- Site Public Contact
- 邮箱:helpdesk@childrensoncologygroup.org
-
首席研究员:
- Jeffrey H. Schwartz
-
Tampa、Florida、美国、33607
- 招聘中
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
接触:
- Site Public Contact
- 电话号码:813-357-0849
- 邮箱:jennifer.manns@baycare.org
-
首席研究员:
- Don E. Eslin
-
-
Georgia
-
Atlanta、Georgia、美国、30329
- 招聘中
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
首席研究员:
- Sarah G. Mitchell
-
接触:
- Site Public Contact
- 电话号码:404-785-0232
- 邮箱:Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Lurie Children's Hospital-Chicago
-
首席研究员:
- Amy L. Walz
-
接触:
- Site Public Contact
- 电话号码:773-880-4562
-
Chicago、Illinois、美国、60637
- 暂停
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Riley Hospital for Children
-
接触:
- Site Public Contact
- 电话号码:800-248-1199
-
首席研究员:
- Marissa Just
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 尚未招聘
- University of Kentucky/Markey Cancer Center
-
接触:
- Site Public Contact
- 电话号码:859-257-3379
-
首席研究员:
- James T. Badgett
-
-
Louisiana
-
New Orleans、Louisiana、美国、70118
- 招聘中
- Children's Hospital New Orleans
-
首席研究员:
- Maria C. Velez-Yanguas
-
接触:
- Site Public Contact
- 电话号码:504-894-5377
-
-
Maine
-
Scarborough、Maine、美国、04074
- 招聘中
- Maine Children's Cancer Program
-
首席研究员:
- Aaron R. Weiss
-
接触:
- Site Public Contact
- 电话号码:207-396-8670
- 邮箱:clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
接触:
- Site Public Contact
- 电话号码:410-955-8804
- 邮箱:jhcccro@jhmi.edu
-
首席研究员:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana-Farber Cancer Institute
-
首席研究员:
- Allison F. O'Neill
-
接触:
- Site Public Contact
- 电话号码:877-442-3324
-
-
Michigan
-
Grand Rapids、Michigan、美国、49503
- 招聘中
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:616-391-1230
- 邮箱:crcwm-regulatory@crcwm.org
-
首席研究员:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic in Rochester
-
接触:
- Site Public Contact
- 电话号码:855-776-0015
-
首席研究员:
- Peter Schoettler
-
-
Mississippi
-
Jackson、Mississippi、美国、39216
- 招聘中
- University of Mississippi Medical Center
-
接触:
- Site Public Contact
- 电话号码:601-815-6700
-
首席研究员:
- Amanda Strobel
-
-
Missouri
-
Kansas City、Missouri、美国、64108
- 招聘中
- Children's Mercy Hospitals and Clinics
-
首席研究员:
- Keith J. August
-
接触:
- Site Public Contact
- 电话号码:816-302-6808
- 邮箱:COGResearchGroup@cmh.edu
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine
-
接触:
- Site Public Contact
- 电话号码:800-600-3606
- 邮箱:info@siteman.wustl.edu
-
首席研究员:
- Frederick S. Huang
-
-
Nebraska
-
Omaha、Nebraska、美国、68114
- 招聘中
- Children's Hospital and Medical Center of Omaha
-
接触:
- Site Public Contact
- 电话号码:402-955-3949
-
首席研究员:
- Jill C. Beck
-
Omaha、Nebraska、美国、68198
- 招聘中
- University of Nebraska Medical Center
-
接触:
- Site Public Contact
- 电话号码:402-559-6941
- 邮箱:unmcrsa@unmc.edu
-
首席研究员:
- Jill C. Beck
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- Hackensack University Medical Center
-
首席研究员:
- Katharine Offer
-
接触:
- Site Public Contact
- 电话号码:551-996-2897
-
Neptune City、New Jersey、美国、07753
- 招聘中
- Jersey Shore Medical Center
-
接触:
- Site Public Contact
- 电话号码:732-776-4240
-
首席研究员:
- Katharine Offer
-
New Brunswick、New Jersey、美国、08903
- 招聘中
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
首席研究员:
- Scott Moerdler
-
接触:
- Site Public Contact
- 电话号码:732-235-8675
-
Newark、New Jersey、美国、07112
- 招聘中
- Newark Beth Israel Medical Center
-
接触:
- Site Public Contact
- 电话号码:973-926-7230
- 邮箱:Christine.Kosmides@rwjbh.org
-
首席研究员:
- Teena Bhatla
-
-
New York
-
Albany、New York、美国、12208
- 招聘中
- Albany Medical Center
-
接触:
- Site Public Contact
- 电话号码:518-262-5513
-
首席研究员:
- Lauren R. Weintraub
-
The Bronx、New York、美国、10467
- 招聘中
- Montefiore Medical Center - Moses Campus
-
接触:
- Site Public Contact
- 电话号码:718-379-6866
- 邮箱:eskwak@montefiore.org
-
首席研究员:
- Alice Lee
-
-
North Carolina
-
Charlotte、North Carolina、美国、28203
- 招聘中
- Carolinas Medical Center/Levine Cancer Institute
-
接触:
- Site Public Contact
- 电话号码:800-804-9376
-
首席研究员:
- Joel A. Kaplan
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center
-
首席研究员:
- Jessica M. Sun
-
接触:
- Site Public Contact
- 电话号码:888-275-3853
-
Greenville、North Carolina、美国、27834
- 招聘中
- East Carolina University
-
接触:
- Site Public Contact
- 电话号码:252-744-1015
- 邮箱:eubankss@ecu.edu
-
首席研究员:
- Andrea R. Whitfield
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest University Health Sciences
-
接触:
- Site Public Contact
- 电话号码:336-713-6771
-
首席研究员:
- Sarah Supples
-
-
North Dakota
-
Fargo、North Dakota、美国、58122
- 招聘中
- Sanford Broadway Medical Center
-
接触:
- Site Public Contact
- 电话号码:701-323-5760
- 邮箱:OncologyClinicalTrialsFargo@sanfordhealth.org
-
首席研究员:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati、Ohio、美国、45229
- 招聘中
- Cincinnati Children's Hospital Medical Center
-
接触:
- Site Public Contact
- 电话号码:513-636-2799
- 邮箱:cancer@cchmc.org
-
首席研究员:
- Brian K. Turpin
-
Cleveland、Ohio、美国、44106
- 招聘中
- Rainbow Babies and Childrens Hospital
-
接触:
- Site Public Contact
- 电话号码:216-844-5437
-
首席研究员:
- Duncan S. Stearns
-
Columbus、Ohio、美国、43205
- 招聘中
- Nationwide Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:614-722-6039
- 邮箱:Melinda.Triplet@nationwidechildrens.org
-
首席研究员:
- Mark A. Ranalli
-
Dayton、Ohio、美国、45404
- 招聘中
- Dayton Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:800-228-4055
-
首席研究员:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma Health Sciences Center
-
接触:
- Site Public Contact
- 电话号码:405-271-8777
- 邮箱:ou-clinical-trials@ouhsc.edu
-
首席研究员:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18103
- 招聘中
- Lehigh Valley Hospital-Cedar Crest
-
接触:
- Site Public Contact
- 电话号码:610-402-9543
- 邮箱:Morgan_M.Horton@lvhn.org
-
首席研究员:
- Jacob A. Troutman
-
Hershey、Pennsylvania、美国、17033
- 招聘中
- Penn State Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:717-531-6012
-
首席研究员:
- Lisa M. McGregor
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Children's Hospital of Philadelphia
-
接触:
- Site Public Contact
- 电话号码:267-425-5544
- 邮箱:CancerTrials@email.chop.edu
-
首席研究员:
- Theodore W. Laetsch
-
Pittsburgh、Pennsylvania、美国、15224
- 招聘中
- Children's Hospital of Pittsburgh of UPMC
-
接触:
- Site Public Contact
- 电话号码:412-692-8570
- 邮箱:jean.tersak@chp.edu
-
首席研究员:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia、South Carolina、美国、29203
- 招聘中
- Prisma Health Richland Hospital
-
首席研究员:
- Stuart L. Cramer
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、美国、29605
- 招聘中
- BI-LO Charities Children's Cancer Center
-
首席研究员:
- Aniket Saha
-
接触:
- Site Public Contact
- 电话号码:864-522-4317
- 邮箱:Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57117-5134
- 招聘中
- Sanford USD Medical Center - Sioux Falls
-
接触:
- Site Public Contact
- 电话号码:605-312-3320
- 邮箱:OncologyClinicalTrialsSF@SanfordHealth.org
-
首席研究员:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis、Tennessee、美国、38105
- 招聘中
- Saint Jude Children's Research Hospital
-
接触:
- Site Public Contact
- 电话号码:888-226-4343
- 邮箱:referralinfo@stjude.org
-
首席研究员:
- Catherine G. Lam
-
Nashville、Tennessee、美国、37232
- 招聘中
- Vanderbilt University/Ingram Cancer Center
-
接触:
- Site Public Contact
- 电话号码:800-811-8480
-
首席研究员:
- Scott C. Borinstein
-
Nashville、Tennessee、美国、37203
- 招聘中
- The Children's Hospital at TriStar Centennial
-
接触:
- Site Public Contact
- 电话号码:615-342-1919
-
首席研究员:
- Clinton M. Carroll
-
-
Texas
-
Austin、Texas、美国、78723
- 招聘中
- Dell Children's Medical Center of Central Texas
-
接触:
- Site Public Contact
- 电话号码:512-628-1902
- 邮箱:TXAUS-DL-SFCHemonc.research@ascension.org
-
首席研究员:
- Shannon M. Cohn
-
Dallas、Texas、美国、75390
- 招聘中
- UT Southwestern/Simmons Cancer Center-Dallas
-
接触:
- Site Public Contact
- 电话号码:214-648-7097
- 邮箱:canceranswerline@UTSouthwestern.edu
-
首席研究员:
- Avanthi T. Shah
-
Fort Worth、Texas、美国、76104
- 招聘中
- Cook Children's Medical Center
-
接触:
- Site Public Contact
- 电话号码:682-885-2103
- 邮箱:CookChildrensResearch@cookchildrens.org
-
首席研究员:
- Chelsee Greer
-
Houston、Texas、美国、77030
- 招聘中
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
接触:
- Site Public Contact
- 电话号码:713-798-1354
- 邮箱:burton@bcm.edu
-
首席研究员:
- Mehmet F. Okcu
-
Houston、Texas、美国、77030
- 招聘中
- UT MD Anderson Cancer Center
-
接触:
- Site Public Contact
- 电话号码:866-632-6789
- 邮箱:askmdanderson@mdanderson.org
-
首席研究员:
- Najat C. Daw
-
San Antonio、Texas、美国、78207
- 招聘中
- Children's Hospital of San Antonio
-
接触:
- Site Public Contact
- 电话号码:210-704-2894
- 邮箱:bridget.medina@christushealth.org
-
首席研究员:
- Julie Voeller
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 招聘中
- University of Virginia Cancer Center
-
接触:
- Site Public Contact
- 电话号码:434-243-6303
- 邮箱:uvacancertrials@hscmail.mcc.virginia.edu
-
首席研究员:
- Brian C. Belyea
-
Norfolk、Virginia、美国、23507
- 招聘中
- Children's Hospital of The King's Daughters
-
接触:
- Site Public Contact
- 电话号码:757-668-7243
- 邮箱:CCBDCresearch@chkd.org
-
首席研究员:
- Melissa S. Mark
-
Richmond、Virginia、美国、23298
- 招聘中
- VCU Massey Comprehensive Cancer Center
-
首席研究员:
- Madhu S. Gowda
-
接触:
- Site Public Contact
- 电话号码:804-628-6430
- 邮箱:CTOclinops@vcu.edu
-
-
Washington
-
Seattle、Washington、美国、98105
- 招聘中
- Seattle Children's Hospital
-
接触:
- Site Public Contact
- 电话号码:866-987-2000
-
首席研究员:
- Sarah E. Leary
-
Tacoma、Washington、美国、98405
- 招聘中
- Mary Bridge Children's Hospital and Health Center
-
接触:
- Site Public Contact
- 电话号码:253-403-1461
- 邮箱:research@multicare.org
-
首席研究员:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- Children's Hospital of Wisconsin
-
首席研究员:
- Angela Steineck
-
接触:
- Site Public Contact
- 电话号码:414-955-4727
- 邮箱:MACCCTO@mcw.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
1 to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female) 2 to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female) 6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
≥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
其他名称:
Given IV
其他名称:
Undergo CT
其他名称:
Undergo MRI
其他名称:
Ancillary studies Undergo ECHO
其他名称:
Undergo MUGA
其他名称:
Undergo PET
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo tissue biopsy
其他名称:
Undergo chest x-ray
其他名称:
Ancillary studies Receive radiation therapy
其他名称:
Undergo blood and stool sample collection
其他名称:
Given IV
其他名称:
Undergo dental x-ray
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
大体时间:Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events. IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Event-free survival (EFS)
大体时间:From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
大体时间:At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
大体时间:At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
大体时间:Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
EFS
大体时间:At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
大体时间:From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
大体时间:At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
大体时间:Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
大体时间:Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
大体时间:Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
大体时间:At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
大体时间:At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
大体时间:At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
合作者和调查者
调查人员
- 首席研究员:Robyn D Gartrell、Children's Oncology Group
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 口腔疾病
- 按部位分类的肿瘤
- 肿瘤
- 组织学类型的肿瘤
- 头颈肿瘤
- 肿瘤、腺体和上皮
- 癌
- 耳鼻喉科疾病
- 咽部肿瘤
- 耳鼻咽喉肿瘤
- 鼻咽疾病
- 咽部疾病
- 鼻咽肿瘤
- 鼻咽癌
- 氨基酸,肽和蛋白质
- 蛋白质
- 杂环化合物,1形
- 杂环化合物
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 手术程序,手术
- 细胞学技术
- 细胞诊断
- 身体现象
- 设备和用品
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 无机化学物质
- 氯化合物
- 氮化合物
- 脱氧胞苷
- 胞苷
- 嘧啶核苷
- 嘧啶
- 元素
- 金属
- 诊断技术,手术
- 化学技术,分析
- 频谱分析
- 金属,重
- 白金化合物
- 电磁现象
- 磁现象
- 过渡元素
- 电磁辐射
- 辐射,电离
- 纳武单抗
- 吉西他滨
- 顺铂
- 1,2-二氨基环己烷柠檬酸铂 II
- 放疗
- 辐射
- 活检
- 标本处理
- 磁共振光谱
- 铂
- X射线
- 幻影,成像
- Fluciclovine F-18
其他研究编号
- NCI-2023-07208
- U10CA180886 (美国 NIH 拨款/合同)
- NCI-2023-07208 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- ARAR2221 (其他标识符:CTEP)
- ARAR2221 (其他标识符:Children's Oncology Group)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.